Patent Docs, a patent law weblog, published an article co-authored by Lippes Mathias partner Joshua Rich discussing the Supreme Court's grant of certiorari in a case involving generic drug marketing practices under the Hatch-Waxman Act. Rich's analysis explores the delicate balance between innovator exclusivity and generic market access, focusing on whether Hikma's marketing of its generic Vascepa constituted active inducement of infringement despite having a skinny label limited to approved indications.